Literature DB >> 25367684

Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.

Francesco Vasuri1, Laura Rocchi, Alessio Degiovanni, Francesca Giunchi, Giovanni Brandi, Davide Treré, Lorenzo Montanaro, Antonia D'Errico-Grigioni.   

Abstract

AIMS: To investigate the immunohistochemical expression of dyskerin, a biomarker involved in ribosome production and telomere maintenance, in human fetal, adult and neoplastic bile ducts, and possible correlations with cholangiocarcinoma aggressiveness. METHODS AND
RESULTS: Sixty consecutive intrahepatic cholangiocarcinomas were collected and used for tissue microarray construction (total: 176 cores); clinical data and follow-up were also collected. Five fetal and 10 normal adult livers were included as controls. Automated immunohistochemistry for dyskerin, p53, and Ki67, and nucleolar silver staining, were performed. In normal livers, dyskerin expression was negative in smaller bile ducts (mean 44.8 μm) and positive in bile ducts of larger diameter (mean 116.1 μm; P < 0.001). Expression was positive in 56.7% of cholangiocarcinomas, and correlated with p53 mutation (P = 0.008) and a higher proliferative (Ki67) index (P = 0.003), which were included as markers of tumour aggressiveness. Finally, dyskerin-positive cholangiocarcinomas showed a negative trend in disease-free survival (P = 0.078) on univariate analysis.
CONCLUSIONS: The non-neoplastic biliary tree seems to progressively lose dyskerin expression from the major branches to the peripheral portal bile ducts. Similarly, intrahepatic cholangiocarcinomas showed two patterns of dyskerin expression, and the dyskerin-positive phenotype seemed to characterize more aggressive cholangiocarcinomas.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  biliary tree; cholangiocarcinoma; dyskerin; histopathology; immunohistochemistry

Mesh:

Substances:

Year:  2014        PMID: 25367684     DOI: 10.1111/his.12480

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

1.  Discovery of new chromen-4-one derivatives as telomerase inhibitors through regulating expression of dyskerin.

Authors:  Jie Quan Wang; Meng Di Yang; Xing Chen; Yang Wang; Liu Zeng Chen; Xiu Cheng; Xin Hua Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

2.  Synthesis, telomerase inhibitory and anticancer activity of new 2-phenyl-4H-chromone derivatives containing 1,3,4-oxadiazole moiety.

Authors:  Xu Han; Yun Long Yu; Duo Ma; Zhao Yan Zhang; Xin Hua Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

3.  MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients.

Authors:  Liping Zhuang; Zhiqiang Meng; Zongguo Yang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

4.  Dyskerin and TERC expression may condition survival in lung cancer patients.

Authors:  Marianna Penzo; Vienna Ludovini; Davide Treré; Annamaria Siggillino; Jacopo Vannucci; Guido Bellezza; Lucio Crinò; Lorenzo Montanaro
Journal:  Oncotarget       Date:  2015-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.